Form 8-K Karuna Therapeutics, For: Aug 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- S&P 500, Nasdaq set for weekly fall as chip stocks slide
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
Karuna Therapeutics Inc. (KRTX) PT Raised to $260 at Stifel
August 8, 2022 3:59 PM EDTStifel analyst Paul Matteis raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $260.00 (from $185.00) while maintaining a Buy rating.
The analyst comments "We rate KRTX shares Buy. Karuna is a biotechnology company focused on the development of novel neuroscience... More
